Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Sarepta Therapeutics Stock

Price
Target price
€17.58

€17.58

2.510%
0.43
2.510%
-
 
02.02.26 / Tradegate WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Sarepta Therapeutics in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Sarepta Therapeutics is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Sarepta

sharewise wants to provide you with the best news and tools for Sarepta, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment

MarketBeat 
0 12.08.25
2 Beaten-Down Stocks That Could Sink Even More in 2026: https://g.foolcdn.com/editorial/images/851531/doctor-and-patient-in-a-hospital-room.jpg
2 Beaten-Down Stocks That Could Sink Even More in 2026

The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make

TheMotleyFool 
0 22.01.26
2 Beaten-Down Stocks to Avoid Right Now: https://g.foolcdn.com/editorial/images/842001/scientist-altering-dna-genome-project.jpg
2 Beaten-Down Stocks to Avoid Right Now

The biotech industry is notoriously volatile. Drugmakers often face significant challenges that send their stocks plummeting. Sometimes that creates an attractive entry point, provided we can

TheMotleyFool 
0 15.11.25
2 Beaten-Down Stocks to Avoid Right Now
2 Beaten-Down Stocks to Avoid Right Now

Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.

Take Teladoc

TheMotleyFool 
0 05.09.25